Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

AGEN - Agenus Inc


IEX Last Trade
5.18
0.190   3.668%

Share volume: 260,155
Last Updated: Fri 30 Aug 2024 09:58:53 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$4.99
0.19
3.81%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
23%
Profitability 18%
Dept financing 25%
Liquidity 14%
Performance 30%
Company vs Stock growth
vs
Performance
5 Days
-11.21%
1 Month
-15.02%
3 Months
-65.92%
6 Months
-65.72%
1 Year
-81.87%
2 Year
-89.94%
Key data
Stock price
$5.18
P/E Ratio 
-0.50
DAY RANGE
$4.97 - N/A
EPS 
-$11.28
52 WEEK RANGE
$4.41 - $27.80
52 WEEK CHANGE
-$0.81
MARKET CAP 
111.095 M
YIELD 
N/A
SHARES OUTSTANDING 
21.572 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/05/2024
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$461,802
AVERAGE 30 VOLUME 
$476,832
Company detail
CEO: Garo Armen
Region: US
Website: http://agenusbio.com/
Employees: 307
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

agenus is an immunology company discovering and developing novel checkpoint modulators, vaccines and adjuvants to treat cancer and other diseases. we are a dedicated group of scientists, researchers, biotechnologists, physicians, and businesspeople working together toward one goal: to discover and develop therapies that can unleash the innate power of the body’s immune system to treat and potentially cure hard-to-treat cancers and other diseases. our product candidates are designed to work by educating and activating the body’s immune system for a precise and potent attack on cancer. our strategy is to help unlock the potential of one of the most exciting breakthrough areas in cancer treatment in decades, and to develop single agent and combination immune-oncology therapies that can help save lives. our approaches are driven by three platform technologies, including: • our antibody platforms, including our proprietary retrocyte display™ and secant® technologies, and our antibody

Recent news